Remdesivir Plus Dexamethasone Reduces Mortality Risk in Patients With COVID-19
Remdesivir plus dexamethasone vs dexamethasone alone reduces the risk of mortality among patients hospitalized with COVID-19.
Related Articles
Two studies describe economic burden, sex differences of long COVID
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 Long COVID can cause substantial economic loss and missed days of work, and it can strike women more often than…
Immunometabolic Effect of Nitric Oxide on Human Macrophages Challenged With the SARS‐CoV2‐Induced Cytokine Storm. A Fluxomic Approach
Human macrophages activated by COVID-19 cytokine storm do not express NOS2. Exogenous administration of NO improves macrophage function in pro-inflammatory conditions. NO significantly alters the…
Antiviral use in US kids seeking care for flu fell to under 60% last year
University of Minnesota http://twin-cities.umn.edu/ 612-625-5000 The prescribing of antiviral drugs for US children and adolescents receiving treatment for influenza was less than 60% in the…
Essential Malaria Drug Artemisinin Shows Signs of Partial Resistance in Children With Severe Malaria
With up to 37.5% of children carrying this resistance mutation the findings suggest that current treatment protocols may be losing effectiveness.
Martin Kulldorf is hopeful RFK Jr will return to evidence-based medicine – Chicago’s Morning Answer with Dan Proft and Amy Jacobson
Martin Kulldorff, former professor of medicine at Harvard University and founding fellow of the Academy for Science and Freedom
A Transition in HRSA’s HIV/AIDS Bureau
Cross-posted from: TargetHIV On October 10, 2024, HRSA published the following announcement: [On October 10, 2…
Povidine-Iodine Remains an Effective Preoperative Skin Antisepsis Option
Povidone-iodine vs chlorohexidine gluconate demonstrated a reduction in deep SSI, but an increased risk for overall and superficial SSI.
Opinion | Chuck Hagel: The Risk of Dragging Politics into the Military
Political independence and ethics are the bedrock of our armed forces. Today, I am concerned that both are in danger.
Nirsevimab 89% effective against RSV hospitalization for babies, CDC estimates
The drug was 88% effective against the need for medical attention among those in their second respiratory virus season.